About: ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies
Creator	Betella, Ilaria Colombo, Ilaria Colombo, Nicoletta Gonzalez-Martin, Antonio Grande, Maria Ledermann, Jonathan Multinu, Francesco Sessa, Cristiana Tomao, Federica Zaccarelli, Eleonora
Source	Medline; PMC
abstract	The rapid spread of severe acute respiratory syndrome coronavirus 2 infection and its related disease (COVID-19) has required an immediate and coordinate healthcare response to face the worldwide emergency and define strategies to maintain the continuum of care for the non-COVID-19 diseases while protecting patients and healthcare providers. The dimension of the COVID-19 pandemic poses an unprecedented risk especially for the more vulnerable populations. To manage patients with cancer adequately, maintaining the highest quality of care, a definition of value-based priorities is necessary to define which interventions can be safely postponed without affecting patients’ outcome. The European Society for Medical Oncology (ESMO) has endorsed a tiered approach across three different levels of priority (high, medium, low) incorporating information on the value-based prioritisation and clinical cogency of the interventions that can be applied for different disease sites. Patients with gynaecological cancer are at particular risk of COVID-19 complications because of their age and prevalence of comorbidities. The definition of priority level should be based on tumour stage and histology, cancer-related symptoms or complications, aim (curative vs palliative) and magnitude of benefit of the oncological intervention, patients’ general condition and preferences. The decision-making process always needs to consider the disease-specific national and international guidelines and the local healthcare system and social resources, and a changing situation in relation to COVID-19 infection. These recommendations aim to provide guidance for the definition of deferrable and undeferrable interventions during the COVID-19 pandemic for ovarian, endometrial and cervical cancers within the context of the ESMO Clinical Practice Guidelines.
has issue date	2020-07-27(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000827
bibo:pmid	32718919
has license	cc-by-nc
sha1sum (hex)	ebb14ba99afe3b4c57ff7bebbfa2d021458feba0
schema:url	https://doi.org/10.1136/esmoopen-2020-000827
resource representing a document's title	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies
has PubMed Central identifier	PMC7388889
has PubMed identifier	32718919
schema:publication	ESMO Open
resource representing a document's body	covid:ebb14ba99afe3b4c57ff7bebbfa2d021458feba0#body_text
is schema:about of	named entity 'ESMO' named entity 'Open access' named entity 'cervical cancer' named entity 'endometrial cancer' named entity 'handwashing' named entity 'blood tests' named entity 'PARPi' named entity 'gynaecological cancer' named entity 'adjuvant chemotherapy' named entity 'mucinous' named entity 'metastatic' named entity 'chemotherapy' named entity 'clinical trial' named entity 'COVID-19 pandemic' named entity 'BSO' named entity 'infectious disease' named entity 'radiation treatment' named entity 'QoL' named entity 'acute care' named entity 'tumour' named entity 'MDT' named entity 'MCBS' named entity 'Adjuvant' named entity 'cervical cancer' named entity 'gynaecological' named entity 'tumour' named entity 'healthcare providers' named entity 'Palliative' named entity 'radiation treatment' named entity 'clinical data' named entity 'histological' named entity 'radiotherapy' named entity 'risk/benefit ratio' named entity 'asymptomatic' named entity 'follow-up' named entity 'CT scan' named entity 'Adjuvant chemotherapy' named entity 'histologically' named entity 'hydronephrosis' named entity 'IB3' named entity 'arterial hypertension' named entity 'International Federation of Gynaecology and Obstetrics' named entity 'outpatient setting' named entity 'asymptomatic' named entity 'COVID' named entity 'outpatient clinics' named entity 'radiologically' named entity 'peritonitis' named entity 'sentinel node biopsy' named entity 'contraindicated' named entity 'Laparoscopy' named entity 'pleural effusion' named entity 'follow-up' named entity 'acute abdominal pain' named entity 'endometrial cancer' named entity 'cytoreductive surgery' named entity 'Ontario' named entity 'COVID-19' named entity 'medical care' named entity 'clinical guidelines' named entity 'Bevacizumab' named entity 'QoL' named entity 'chemotherapy' named entity 'comorbidities' named entity 'uterine cancer' named entity 'COVID' named entity 'curative intent' named entity 'radiation oncology' named entity 'COVID' named entity 'gynaecological' named entity 'surgical management' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software